Editas Medicine, Inc. (EDIT) earnings
EDIT earnings moved a median of -0.69% by the close. Quarterly and annual EDIT reports and results, each read against the price at its own news timestamp. Back to the EDIT overview →
25 measured EDIT earnings events.
Where these EDIT earnings landedvs 25 measured EDIT earnings reactions
| Middle 50% of EDIT earnings reactions | -5.58% to +2.84% |
|---|---|
| Median reaction (to close) | -0.69% |
| Measured reactions | 25 |
Point-in-time · zero look-ahead
Half of the 25 EDIT earnings events with a measured close landed between -5.58% and +2.84%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Editas Medicine Announces Second Quarter 2026 Results and Business Updates | Press release | +4.96% | +2.84% | |
| Form 10-Q Editas Medicine, Inc. For: Jun 30 | SEC filing · Form 10-Q | +4.96% | +2.84% | |
| Editas Medicine Announces First Quarter 2026 Results and Business Updates | Press release | +1.32% | +0.66% | |
| Form 10-Q Editas Medicine, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.97% | +2.42% | |
| Form 10-K Editas Medicine, Inc. For: Dec 31 | SEC filing · Form 10-K | +4.98% | +9.54% | |
| Editas Medicine Announces Third Quarter 2025 Results and Business Updates | Press release | -2.42% | -5.97% | |
| Form 10-Q Editas Medicine, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.05% | +2.70% | |
| Editas Medicine Announces Second Quarter 2025 Results and Business Updates | Press release | +7.85% | +25.71% | |
| Form 10-Q Editas Medicine, Inc. For: Jun 30 | SEC filing · Form 10-Q | +7.85% | +25.71% | |
| Editas Medicine Announces First Quarter 2025 Results and Business Updates | Press release | -2.58% | -3.23% | |
| Form 10-Q Editas Medicine, Inc. For: Mar 31 | SEC filing · Form 10-Q | -2.58% | -3.23% | |
| Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May | Press release | -1.38% | -12.50% | |
| Form 10-K Editas Medicine, Inc. For: Dec 31 | SEC filing · Form 10-K | +2.59% | -7.77% | |
| Editas Medicine Announces Third Quarter 2024 Results and Business Updates | Press release | -3.10% | -0.69% | |
| Form 10-Q Editas Medicine, Inc. For: Sep 30 | SEC filing · Form 10-Q | -3.10% | -0.69% | |
| Editas Medicine Announces Second Quarter 2024 Results and Business Updates | Press release | -5.33% | -15.78% | |
| Form 10-Q Editas Medicine, Inc. For: Jun 30 | SEC filing · Form 10-Q | -3.20% | -3.78% | |
| Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update | Press release | -1.11% | +0.37% | |
| Editas Medicine Announces First Quarter 2024 Results and Business Updates | Press release | -5.28% | -6.76% | |
| Form 10-Q Editas Medicine, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.54% | +7.13% | |
| Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events | Press release | -0.36% | +1.44% | |
| Form 10-K Editas Medicine, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.97% | -10.89% | |
| Editas Medicine Announces Third Quarter 2023 Results and Business Updates | Press release | +7.45% | +14.62% | |
| Form 10-Q Editas Medicine, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.18% | -1.42% | |
| Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events | Press release | -3.32% | -5.58% |
Keep exploring
More EDIT: analyst actions → · SEC filings → · EDIT overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cerus Corporation (CERS) | 255 | +0.09% | 52% |
| Avalon GloboCare Corp. (AVCO) | 254 | 0.00% | 41% |
| Nevro Corp. (NVRO) | 253 | 0.00% | 49% |
| DarioHealth Corp. (DRIO) | 252 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.